☆ 4.7 Article

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma

Ying Wang et al.

Summary: The combination of anti-BCMA and anti-CD19 CAR T cells has shown durable response in patients with relapsed or refractory MM, with manageable long-term safety profile. The overall response rate was 92%, and complete response or better was observed in 60% of patients. Adverse events mainly included cytokine release syndrome and neurotoxic events.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Cell Biology

CAR T Cell Locomotion in Solid Tumor Microenvironment

Duy T. Nguyen et al.

Summary: This article discusses the important role of the tumor microenvironment in CAR-T cell therapy and explains the advantages and limitations of preclinical models.

CELLS (2022)

Add to Collection

Article Hematology

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Di Wang et al.

Summary: CT103A, a fully human BCMA-specific CAR T-cell therapy, has shown safety and high efficacy in patients with relapsed/refractory multiple myeloma, including those who had prior exposures to murine BCMA CAR therapy. Its overall response rate reaches 100%, with a significant portion achieving complete response or stringent complete response. Hematologic toxicities are common adverse events, but no immune effector cell-associated neurotoxicity syndrome was observed. Detection of CAR transgenes and median CAR transgene persistence support the potential of CT103A as a promising therapy for RRMM.

BLOOD (2021)

Add to Collection

Review Oncology

Born to survive: how cancer cells resist CAR T cell therapy

Jean Lemoine et al.

Summary: Although chimeric antigen receptor T cells have shown remarkable efficacy in patients with chemo-resistant hematologic malignancies, a significant portion still resist or relapse. This resistance may be attributed to CAR T cell dysfunction, a hostile tumor microenvironment, or resistant cancer cells. In this review, intrinsic resistance mechanisms of cancer cells to CAR T cell therapy and potential strategies to overcome them are discussed.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Nikhil C. Munshi et al.

Summary: The phase 2 study confirmed the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma, with a majority of patients achieving responses and 26% achieving MRD-negative status. Despite the high response rate, almost all patients experienced grade 3 or 4 toxic effects, including hematologic toxic effects and cytokine release syndrome.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Hematology

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations

Laura Rosinol et al.

Summary: This review identifies two types of soft-tissue involvement in multiple myeloma: EMD and PS. EMD disease is associated with high-risk cytogenetics, therapy resistance, and worse prognosis. For patients with PS involvement, a proteasome inhibitor-based regimen may be the best option.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Add to Collection

Article Immunology

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials

Yimei Que et al.

Summary: Based on the analysis of clinical trial results of anti-BCMA CAR-T cell therapy, it was found that patients with extramedullary multiple myeloma could benefit from this treatment in terms of safety, efficacy, and pharmacokinetics, although they had shorter overall survival and progression-free survival compared to non-extramedullary multiple myeloma patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19-positive malignancies

Sanmei Wang et al.

Summary: CAR T cells targeting CD19 have shown impressive clinical responses in lymphoid malignancies, but resistance and relapse remain challenges. Combining CAR T cells with selective inhibitors of nuclear export (SINEs) targeting XPO1 may reduce the risk of tumor escape, although simultaneous use of SINEs and CAR T cells may impair CAR T cell function. Sequential use of SINEs and CAR T cells could potentially enhance the anti-tumor efficacy of CAR T cells.

ONCOLOGY REPORTS (2021)

Add to Collection

Review Oncology

The nuclear export protein XPO1-from biology to targeted therapy

Asfar S. Azmi et al.

Summary: XPO1 plays a crucial role in cellular homeostasis and cancer development, with its inhibitor selinexor clinically validated and approved for multiple myeloma and diffuse large B cell lymphoma treatment.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma

Lina Zhang et al.

Summary: Anti-BCMA CAR T therapy is effective and safe for patients with R/R MM, with dual epitope-binding CAR T cells achieving the best therapy outcomes and humanized CAR T cells having the best safety profile. Older patients, heavily pre-treated patients, or those who received lower dose of CAR T cells may have worse outcomes.

ANNALS OF MEDICINE (2021)

Add to Collection

Review Oncology

Extramedullary multiple myeloma

Manisha Bhutani et al.

LEUKEMIA (2020)

Add to Collection

Review Cell Biology

The double dealing of cyclin D1

Guergana Tchakarska et al.

CELL CYCLE (2020)

Add to Collection

Review Oncology

Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors

Giovanni Fuca et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Hematology

Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia

Jeremy D. Rubinstein et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Add to Collection

Review Immunology

CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape

Alba Rodriguez-Garcia et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Oncology

Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition

Isabel Jimenez et al.

JOURNAL OF NEURO-ONCOLOGY (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells

Sareetha Kailayangiri et al.

MOLECULAR THERAPY (2019)

Add to Collection

Article Hematology

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma

Margot J. Pont et al.

BLOOD (2019)

Add to Collection

Article Medicine, General & Internal

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Hematology

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

Daniel W. Lee et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)

Add to Collection

Article Oncology

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy

Paul M. Tyler et al.

MOLECULAR CANCER THERAPEUTICS (2017)

Add to Collection

Review Oncology

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

Shaji Kumar et al.

LANCET ONCOLOGY (2016)

Add to Collection

Review Oncology

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

C. Fernandez de Larrea et al.

LEUKEMIA (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.